# First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies

> **NCT04763083** · PHASE1 · UNKNOWN · sponsor: **NovalGen Ltd.** · enrollment: 90 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukaemia
- Small Lymphocytic Lymphoma
- Mantle Cell Lymphoma
- Follicular Lymphoma
- Diffuse Large B Cell Lymphoma
- Non-small Cell Lung Cancer (NSCLC)
- Malignant Melanoma

## Interventions

- **DRUG:** NVG-111

## Key facts

- **NCT ID:** NCT04763083
- **Lead sponsor:** NovalGen Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-05-14
- **Primary completion:** 2023-12
- **Final completion:** 2025-12
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2023-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04763083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04763083, "First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04763083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*